Clinicians discuss how type 2 inflammation informs treatment decisions across AD, prurigo nodularis, CSU, and bullous pemphigoid.
|Articles|March 2, 2002
Cosmetic Conundrums with Zoe Diana Draelos, M.D.
Q. What factors determine the SPF performance of a given sunscreen?A. The SPF is the sun protection factor afforded by a given sunscreen. It is determined by dividing the lower back of untanned individuals is into small test sites which are exposed to UVB light until a minimum amount of erythema develops, known as the MED. Lightproof barriers are placed around the test sites to prevent light contamination from one test site to another. Once the MED for the test subject has been determined, the subject is invited to return to the test site the next day for application of sunscreen. The sunscreen is placed on the test sites and allowed to dry. The skin is then exposed to UVB light at the expected SPF of the sunscreen product. The expected SPF is roughly determined by spectrophotometric absorption. The amount of UVB light required to obtain the same degree of erythema as the preceding day is determined and the SPF calculated.
Advertisement
Advertisement
Related to this article
A pediatric dermatologist explains how CALM count, size, age, and associated findings separate benign spots from neurofibromatosis type 1 and its mimics.
At a Dermatology Times Case-Based Roundtable, Vishal A. Patel, MD, led a discussion on treatment selection, tolerability, and individualized care for patients with advanced basal cell carcinoma.
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
October brought FDA approvals in urticaria and HSV, new regulatory filings, and phase 3 advances in HS, psoriasis, and rare diseases.
Gaurav Singh, MD, explores how gene expression profiling may improve melanoma risk stratification, surveillance, and individualized care.
A 2026 study links Agent Orange exposure to higher odds of acral melanoma in US veterans, highlighting the importance of early detection.
Phase 2 BEACON findings published in JAMA Dermatology demonstrate rapid improvements in disease activity and skin-related quality of life with oral brepocitinib.
Advertisement
Advertisement
Trending on Dermatology Times
1
Phase 3 Trial Supports Risankizumab for Pediatric Psoriasis
2
Dermatology Times Monthly FDA and Pipeline Review: October 2026
3
Brepocitinib Clears Skin in 69% of Cutaneous Sarcoidosis Patients
4
Veradermics Reports Sustained Hair Growth With VDPHL01 at 1 Year
5